Revenue
$0.75m
+24.8% ↑ vs $0.6m
Reported loss narrowed in dollar terms but operating cash outflow grew, drawing cash down 17.8% and total equity 13.4% over the period.
Revenue context before the current result.
EBITDA margin across covered periods.
Operating cash flow across covered periods.
Operating working-capital absorption or release by reporting period.
Key metrics
HY22 vs HY21
Revenue
$0.75m
+24.8% ↑ vs $0.6m
Net profit after tax
−$1.3m
+13.3% ↑ vs −$1.5m
Net cash inflow from operating activities
−$1.7m
-9.3% ↓ vs −$1.6m
Declared dividend per share
0.0c
— vs —
Profit before tax
−$1.3m
+13.3% ↑ vs −$1.5m
Cash and cash equivalents
$3.7m
-17.8% ↓ vs $4.5m
Total assets
$10.3m
-15.0% ↓ vs $12.2m
What changed
Because the prior comparable revenue base was affected by IFRS 15 timing on a Zimbabwe shipment, the reported revenue, PBT and NPAT growth percentages carry a basis-discontinuity caveat and should not be read as clean like-for-like rates.
Cash and equivalents fell to NZ$3.7m from NZ$4.5m, a NZ$0.8m draw in six months. Borrowings of NZ$0.4m were fully repaid to zero, and total equity declined 13.4% to NZ$9.7m, consistent with the period loss and no new capital.
Trade receivables collapsed to NZ$7k from NZ$0.2m, while inventories rose 13.3% to NZ$0.7m.
What matters
Against the NZ$3.7m balance, the half-year operating outflow of NZ$1.7m implies roughly twelve to fourteen months of cover at the current burn rate before a further capital event is required. Capex was zero versus NZ$0.1m last year, so the cash consumption is essentially operating, not investment-related.
Working capital signals warrant attention. Trade debtors essentially zeroed out while inventory built — receivable days fell from 47.9 to 1.7 while inventory days remained elevated at 169. Combined with the small revenue base, this points to lumpy, cash-on-shipment customer behaviour rather than a stable receivables book, and to stock held against expected but not yet contracted orders.
The commercial story remains forward-leaning. Management cites 35% growth in Single Use Sensor unit sales, first sales into Eastern Europe, and an anticipated private Health Check placement under the SWXT relationship. These are leading indicators rather than realised earnings drivers; the financial statements still show a sub-scale business well short of operating breakeven.
Expectations
The FY21 reference point reflects a different statutory magnitude and does not produce a meaningful second-half shape signal for this period.
What the result does support is that revenue is growing off a small base and unit volumes are scaling. What it does not support is a near-term path to operating cash breakeven, nor does it address when commercial milestones in Vietnam, Mexico, Eastern Europe or the SWXT partnership translate to a revenue level capable of covering current operating costs.
Quality of result
Operating cash outflow worsened by NZ$0.1m year on year, so cash conversion deteriorated against the prior comparable half. The reported revenue and loss improvements should be read against a prior comparable base that included the IFRS 15 timing effect on a Zimbabwe shipment, which is why the headline growth percentages have been flagged with a basis-discontinuity caveat and not cited as specific rates here.
Repayment of NZ$0.4m of borrowings to zero strengthens the legal balance sheet but consumed cash that the operating business cannot currently replenish. Inventory build to NZ$0.7m carries forward to future periods as either fulfilled orders or written-down stock; at the current revenue run-rate that is roughly a year of sales sitting on the balance sheet.
In substance, the durable signal is volume growth in Single Use Sensors. The less durable signals are the receivables collapse to near zero and the absolute loss reduction, both of which reflect period-end timing more than a step change in operating economics.
Unresolved
This briefing cannot assess management's specific commercial pipeline, contract values, or the probability that announced channel partners translate to revenue in any defined timeframe.
Chat
Ask follow-up questions about Truscreen Group's HY22 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load analytical metrics.
Open to load key metrics.
TruScreen Half Year Report September 2021
HY22 / financial reportTruScreen Results Announcement Template September 2021
HY22 / results announcementTruScreen September 2021 Results Announcement
HY22 / results releaseTruScreen Half Year Results Announcement 30 September 2020
HY21 / results releaseTruScreen Results Template 30 September 2020
HY21 / results announcementTruScreen Unaudited Interim Condensed Financial Statements 30 September 2020
HY21 / financial reportFinancial Results Announcement March 2021
FY21 / results announcementFinancial Results Announcement March 2021
FY21 / results releaseTruscreen Preliminary Final Report March 2021
FY21 / financial reportAnnual Shareholder Meeting Presentation
HY22 / commentaryRelated insights
Cross-company views selected from the metrics in this briefing.
Revenue growth context
Revenue growth was 24.8% for this reporting period.
Working-capital pressure
Inventory days were 169 days, -17 days versus the prior comparable period.
Earnings quality and statutory distortions
PBT and NPAT growth diverged by 0.0pp.
ROE and capital efficiency
ROE was -13.0%, +0.5pp versus the prior comparable period.
Get the next Truscreen Group briefing and related NZX reporting-season updates by email.